By admin 
CureSearch for Children’s Cancer, a leading national non-profit organization dedicated to ending childhood cancer by driving targeted and innovative research, has officially announced the appointment of Osama Alsaleh to its Board of Directors. The strategic addition of Alsaleh, a recognized leader in healthcare technology, venture capital, and global health equity, marks a significant step in the organization’s mission to bridge the gap between laboratory research and clinical application. Alsaleh’s extensive background in fostering strategic partnerships and navigating the complexities of the healthcare innovation ecosystem is expected to provide CureSearch with the necessary expertise to accelerate the development of life-saving treatments for pediatric cancer patients.
As the current Head of Partnerships at Plug and Play Health—one of the world’s most active venture capital firms and a premier global innovation platform—Alsaleh brings a unique perspective on how emerging technologies can be harnessed to solve systemic healthcare challenges. His appointment comes at a critical juncture for CureSearch, as the organization continues to refine its "venture philanthropy" model, which seeks to de-risk high-potential pediatric cancer research to attract the private investment necessary for large-scale clinical trials.
A Career Defined by Innovation and Health Equity
Osama Alsaleh’s professional trajectory is characterized by a consistent focus on the intersection of technology, regulatory compliance, and social impact. Before his current role at Plug and Play Health, Alsaleh held senior positions at Oracle Health (formerly Cerner Corporation), where he was instrumental in shaping the company’s approach to global health initiatives. One of his most notable achievements was spearheading the creation of Oracle’s health equity team. In this capacity, he developed transformative strategies aimed at addressing the social determinants of health (SDOH), ensuring that technological advancements in healthcare are accessible to underserved and marginalized populations.
During his tenure at Oracle, Alsaleh also served on the Oracle Charitable Foundation Clinical Decision Committee. In this role, he contributed to the evaluation and allocation of more than $42 million in healthcare grants. This experience provided him with deep insights into the philanthropic landscape and the rigorous vetting processes required to ensure that capital is deployed effectively to drive measurable health outcomes. His work with the foundation mirrored the core objectives of CureSearch: identifying high-impact projects that have the potential to change the standard of care but lack the initial funding to move forward.
Beyond the private sector, Alsaleh has been a frequent advisor to government agencies and international bodies. His expertise in regulatory compliance and quality reporting measures has seen him collaborate with the Centers for Medicare & Medicaid Services (CMS) on various initiatives. Notably, he served as a resource for the White House COVID-19 Taskforce and the U.S. State Department, offering strategic guidance during the height of the global pandemic. His career also includes impactful stints and collaborations with the World Bank Group and the World Health Organization (WHO), where he advocated for sustainable, technology-driven solutions to global health crises.
Addressing the Pediatric Cancer Funding Gap
The primary motivation behind Alsaleh’s alignment with CureSearch is a recognized disparity in how medical innovation is funded. While adult oncology receives billions of dollars in private and public investment annually, pediatric oncology remains significantly underfunded. According to data from the National Cancer Institute (NCI), only about 4% of federal funding for cancer research is specifically dedicated to childhood cancers. This "funding gap" often prevents promising pediatric therapies from moving past the initial discovery phase—a phenomenon known in the industry as the "Valley of Death."
In his statement following the appointment, Alsaleh highlighted this systemic issue. "Throughout my work, I have consistently observed that innovations focused on pediatrics, particularly pediatric oncology, remain significantly underrepresented within mainstream venture capital and innovation ecosystems," Alsaleh remarked. "By leveraging my network across venture capital, startups, healthcare institutions, and technology companies, I aim to help attract new technologies, strategic partners, and resources that can accelerate progress toward cures for children with cancer."
The challenge is not merely a lack of scientific breakthroughs but a lack of commercial incentive. Because pediatric cancers are considered "rare diseases" in the context of the broader pharmaceutical market, many large biotech firms hesitate to invest the hundreds of millions of dollars required for pediatric-specific clinical trials. CureSearch addresses this by providing the "seed" funding and strategic oversight necessary to move research to a point where it becomes an attractive investment for the private sector.
The Strategic Vision of CureSearch’s Leadership
The Board of Directors at CureSearch, led by Chair Jared Brancazio, views Alsaleh’s appointment as a vital component of the organization’s long-term growth strategy. Brancazio emphasized that the complexities of modern oncology require a multi-disciplinary approach that blends scientific rigor with financial and technological savvy.
"Osama brings a unique and highly valuable perspective to CureSearch," said Brancazio. "His ability to connect innovation, investment, and healthcare will help expand our reach and unlock new opportunities to advance critical research for children with cancer. We are excited to have him join the board at this important time for our organization."
The "important time" Brancazio refers to is a period of rapid evolution in cancer treatment, including the rise of personalized medicine, CAR-T cell therapy, and AI-driven drug discovery. By bringing in a board member who understands the "startup" mentality and the venture capital lifecycle, CureSearch is positioning itself to be more than a traditional grant-making body; it is becoming a facilitator of a modern, efficient research pipeline.
Broader Implications for Pediatric Research and Venture Philanthropy
The addition of a venture capital expert like Alsaleh to a non-profit board reflects a broader trend in the philanthropic sector known as "Venture Philanthropy." This model applies the principles of venture capital—such as rigorous due diligence, performance-based milestones, and active management—to the world of charitable giving. For CureSearch, this means not only providing funds but also providing the infrastructure, regulatory guidance, and industry connections that researchers need to succeed.
The implications of this appointment extend beyond the immediate operations of CureSearch. It signals to the broader healthcare industry that pediatric oncology is a viable and necessary frontier for technological innovation. As AI and machine learning continue to revolutionize how drugs are developed, Alsaleh’s background in technology and partnerships will be crucial in ensuring that pediatric patients are not left behind in the digital health revolution.
Furthermore, Alsaleh’s focus on health equity will likely influence how CureSearch selects its research projects. In the United States, pediatric cancer survival rates have improved significantly over the last few decades, but disparities remain based on socioeconomic status, race, and geographic location. By integrating equity-focused strategies into the board’s decision-making process, CureSearch can ensure that new treatments are developed with accessibility and inclusivity in mind from the outset.
A Chronology of Collaborative Progress
The timeline of Alsaleh’s career demonstrates a steady progression toward this leadership role at CureSearch. From his early days at Cerner, where he focused on the foundational IT infrastructure of healthcare, to his strategic roles at Oracle where he managed multi-million dollar philanthropic portfolios, Alsaleh has spent two decades building the skills necessary to bridge the public and private sectors.
His current role at Plug and Play Health serves as the final piece of the puzzle. Plug and Play is known for its "accelerator" model, which connects startups with corporate giants to speed up the go-to-market process. Applying this "acceleration" mindset to pediatric cancer research could drastically reduce the time it takes for a discovery in a university lab to reach a child in a hospital bed.
As CureSearch welcomes Osama Alsaleh, the organization reinforces its commitment to a future where every child diagnosed with cancer has a guaranteed path to a cure. By combining the heart of a non-profit with the strategic mind of a venture capitalist, CureSearch is setting a new standard for how the world fights childhood cancer. The organization continues to invite the global healthcare and investment communities to join them in this mission, recognizing that the complexities of pediatric oncology cannot be solved by any single entity, but through the power of strategic, cross-sector collaboration.
About CureSearch for Children’s Cancer
CureSearch for Children’s Cancer is a national non-profit foundation that accelerates the search for cures for the 15,000 children diagnosed with cancer each year in the United States. Since its inception, CureSearch has been a pioneer in pediatric cancer research, funding clinical trials and laboratory studies that have led to significant advancements in treatment and survival rates. Through its unique research model, CureSearch focuses on high-impact projects that have the greatest potential to reach the clinic quickly, ensuring that children have access to the most advanced therapies available. With the addition of Osama Alsaleh to its Board of Directors, the organization is poised to further its reach and impact in the global effort to end childhood cancer.
